50% Off Your Order*
Easter Savings!!
Availability: In stock
Unit Size | 5 mg/vial |
Unit Quantity | 1 vial |
Purity (HPLC) | 99.9% |
Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
Molecular Formula | C46H56N12O6 |
Molecular Weight | 872.45 |
Appearance | lyophilized White Powder |
Source | Chemical Synthesis |
Storage | Lyophilized GHRP-6 is Stable at room Temperature for 90 days, however it is best to store in a freezer below - 8c for any extended period of time. After reconstitution GHRP-6 should be refrigerated at temperatures not to exceed 35 F. |
Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
GHRP-6 (growth hormone releasing peptide 6) is a synthetic compound made of six amino acids. It can elicit the release of growth hormone (GH)1. Early work on GHRP-6 and similar peptides indicated that they have no structural similarity to growth hormone releasing hormone, however2. There are two analogs of GHRP-6; GHRP-6 peptide and [D-Lys-3]-GHRP-6. [D-Lys-3]-GHRP-6 has an antagonist effect on the GH secretagogue receptor (GHS-R), or the receptor for ghrelin3. Therefore, such a peptide may be used in animal studies that assess the role of this important biomolecule in various processes related to hunger and metabolic regulation. For example, ghrelin may have a role in enhancing the release of insulin in response to food intake, through the release of GLP-1 from specialized cells in the intestine4. [D-Lys-3]-GHRP-6 has demonstrated the ability to counteract this effect4. It may also be used to determine the locations of the GHS-R, e.g. in the ventral tegmental area of the brain3. [D-Lys-3]-GHRP-6 has demonstrated the ability to reduce the extent of DNA synthesis in the gastric glands of infant rats, indicating a role for ghrelin in the development of the stomach after birth5.
The GHRP-6 peptide, on the other hand, has a dose-dependent agonist effect on the GHS receptor6. However, it appears not to match ghrelin in terms of specificity6. GHRP-6 has demonstrated positive effects on organ growth and regeneration in various studies. Its administration resulted in a threefold increase in the migration, but not proliferation, of rat-intestine epithelial cells, indicating a role for the peptide in restoring gut function7. Intraperitoneal GHRP-6 peptide (at a concentration of 120 μg/kg) also significantly inhibited the effects of an animal model of multiple organ damage (i.e. ischemia-reperfusion injury)7. A combination of GHRP-6 and recombinant human epidermal growth factor (administered at concentrations of either 100 or 600 μg per kg) had a significantly detrimental effects on the neurological damage expected as a result of experimentally-induced ischemic stroke in gerbils8.
References: 1. Pimentel-Filho FR, Ramos-Dias JC, Ninno FB, Facanha CF, Liberman B, Lengyel AM. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism. Clinical endocrinology. 1997;46(3):295-300. 2. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. European journal of endocrinology / European Federation of Endocrine Societies. 1997;136(5):445-460. 3. St-Onge V, Watts A, Abizaid A. Ghrelin enhances cue-induced bar pressing for high fat food. Hormones and behavior. 2015;78:141-149. 4. Gagnon J, Baggio LL, Drucker DJ, Brubaker PL. Ghrelin Is a Novel Regulator of GLP-1 Secretion. Diabetes. 2015;64(5):1513-1521. 5. Bittar NM, Zulian JG, Ogias D, Gama P. Ghrelin and GHS-R in the rat gastric mucosa: Are they involved in regulation of growth during early weaning? Nutrition (Burbank, Los Angeles County, Calif.). 2016;32(1):101-107. 6. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. 7. Cibrian D, Ajamieh H, Berlanga J, et al. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clinical science (London, England : 1979). 2006;110(5):563-573. 8. Subiros N, Perez-Saad HM, Berlanga JA, et al. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurological research. 2015:1743132815y0000000089.